Information Provided By: 
Fly News Breaks for June 12, 2017
MDSO
Jun 12, 2017 | 07:09 EDT
KeyBanc says that industry guidelines recently adopted by the EU should be a catalyst for risk-based monitoring technologies, or RBM. The firm says that Medidiata is the HCT it covers which is most exposed to RBM. It thinks that the company's revenue from RBM has reached a $50M annual run rate, while further adoption of RBM should accelerate adoption of its other SaaS tools. KeyBanc raised its price target on the stock to $84 from $83 and keeps an Overweight rating on the shares.
News For MDSO From the Last 2 Days
There are no results for your query MDSO
